Trex Company enters the post-earnings week with a split personality: short sellers have been adding exposure at the fastest pace in months, yet options traders just pivoted sharply toward calls. The stock closed at $40.20, up 3.6% on the week after Q1 results landed on May 7.
Short interest is the most meaningful single data point on this name right now. It has climbed to 9.63% of the free float — up from roughly 8.6% at the start of April and the highest reading since at least early March. That jump, adding more than 1 percentage point in a month, is not random noise. Bears appear to be rebuilding positions around the housing-adjacent cyclical thesis: tariff exposure on raw materials, a sluggish remodeling cycle, and a concentrated distribution channel all give pessimists a framework. Days to cover stands at 5.6 per the latest FINRA print. The borrow market, however, gives bears no edge. Availability is extremely loose — utilization barely touches 1.85%, a fraction of the 52-week peak near 26% — and cost to borrow is running at just 0.36%, down more than 30% over the past month. Shorts can get into this name cheaply and easily.
What makes the setup interesting is the options market moving in the opposite direction. The put/call ratio dropped sharply this week to 1.06, more than 1.3 standard deviations below its 20-day average of 1.57. For most of April and into early May, the PCR was hovering above 2.0 — heavily skewed toward puts. The abrupt shift toward calls after earnings suggests some of that defensive hedging was unwound on the Q1 result, with buyers rotating into upside exposure. That's a meaningful change in options posture in a short span.
The Street is divided in a way that mirrors the positioning split. Bulls point to a Q1 beat and the company's durable share in wood-alternative decking, with UBS lifting its target to $59 this week — maintaining Buy. On the other side, Barclays holds Underweight with a $35 target and BofA keeps Underperform at $42, both below the current price. Stifel, sitting at Hold, cut its target to $40 — right in line with where the stock is trading. The mean analyst target is $47.94, implying about 19% upside from here, but the distribution is wide and the bears are not fringe voices. Valuation gives neither camp a clean win: the PE has drifted to 22.6x and EV/EBITDA to 12.6x, both off their recent peaks, suggesting the stock has cheapened slightly through the selloff — not dramatically re-rated. The EPS surprise factor score at 74 out of 100 indicates a solid recent track record on beats, though the 12-month forward EPS growth score of just 14 points to muted growth expectations ahead.
Wellington Management's reported addition of more than 5 million shares (as of December 2025 data) was one of the larger institutional moves visible in the holder table. BlackRock and Vanguard both remain above 9% each, with BlackRock adding roughly 200,000 shares through April. Citadel and D.E. Shaw both appear as newer or substantially larger holders — both were at or near minimal positions before year-end 2025. Insider activity is more modest in recent weeks. Director B. Andrew Rose bought just over 12,000 shares at prices around $40 in early March, shortly after CEO Bryan Fairbanks and the COO both sold shares in connection with equity awards. The director buy is constructive in direction but not material in size.
The clearest watch item for the week ahead is whether the post-earnings PCR compression holds. A ratio that dropped from above 2.0 to 1.06 in two sessions either signals genuine sentiment shift or represents transient hedge unwinds — the next few sessions of options flow will clarify which.
See the live data behind this article on ORTEX.
Open TREX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
